Cytomedix Announces Expansion of Phase 2 Study to Treat Post-Acute Ischemic Stroke at up to 15 U.S. Clinical Sites

Cytomedix has received a recommendation from the Data Safety Monitoring Board (DSMB) that it continue its Phase 2 trial continue. This trial uses Cytomedix's stem cell populations derived from patients' own bone marrow to treat for ischemic stroke.... [more]

View complete Press Release article